Autopsy report · NCT00784524
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Cause of deathSlow enrollment
“Slow accrual”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 5 years 10 months before it stopped.
- 14 participants enrolled.
- Results were posted on the registry 4 years 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Sponsor type
- University, hospital or other
- Conditions
- Breast Cancer
- Interventions
- allogeneic large multivalent immunogen breast cancer vaccine; aldesleukin
- Participants
- 14
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.